Drugs / AcNK-Sup003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06693973 | Dec 2023 → Jan 2026 overdue | B-cell non-Hodgkin lymphoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07345741 | Dec 2025 → Dec 2029 expected | B-cell non-Hodgkin lymphoma | Donghua Zhang | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AcNK-Sup003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07345741 ↗ |
| Modality | Cell therapy | “This novel approach yields a non-genetically modified NK cell” NCT06693973 ↗ |